181 related articles for article (PubMed ID: 12115576)
21. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
Beck SD; Patel MI; Sheinfeld J
J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
[TBL] [Abstract][Full Text] [Related]
22. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance.
Thompson PI; Nixon J; Harvey VJ
J Clin Oncol; 1988 Oct; 6(10):1597-603. PubMed ID: 2459319
[TBL] [Abstract][Full Text] [Related]
23. The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan.
Badcock G; Pigott C; Goepel J; Andrews PW
Cancer Res; 1999 Sep; 59(18):4715-9. PubMed ID: 10493530
[TBL] [Abstract][Full Text] [Related]
24. An unusual late relapse in pathologic stage I non-seminomatous germ cell tumor: case report and review of the literature.
Bilgrami S; Chen L; Shafi N; Synnott V; Greenberg B
Urol Int; 1994; 53(3):176-8. PubMed ID: 7544042
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis.
Albers P; Miller GA; Orazi A; Ulbright TM; Albers J; Donohue JP; Foster RS
Cancer; 1995 Feb; 75(3):844-50. PubMed ID: 7828136
[TBL] [Abstract][Full Text] [Related]
26. Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.
Mazumdar M; Bacik J; Tickoo SK; Dobrzynski D; Donadio A; Bajorin D; Motzer R; Reuter V; Bosl GJ
J Clin Oncol; 2003 Jul; 21(14):2679-88. PubMed ID: 12860944
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
[TBL] [Abstract][Full Text] [Related]
28. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours.
Andrews PW; Casper J; Damjanov I; Duggan-Keen M; Giwercman A; Hata J; von Keitz A; Looijenga LH; Millán JL; Oosterhuis JW; Pera M; Sawada M; Schmoll HJ; Skakkebaek NE; van Putten W; Stern P
Int J Cancer; 1996 Jun; 66(6):806-16. PubMed ID: 8647654
[TBL] [Abstract][Full Text] [Related]
30. Secreting germ cell tumors of the central nervous system (CNS). First results of the cooperative German/Italian pilot study (CNS sGCT).
Calaminus G; Andreussi L; Garré ML; Kortmann RD; Schober R; Göbel U
Klin Padiatr; 1997; 209(4):222-7. PubMed ID: 9293454
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Int J Androl; 1998 Oct; 21(5):283-8. PubMed ID: 9805244
[TBL] [Abstract][Full Text] [Related]
32. Serum markers in germ cell neoplasms.
Bartlett NL; Freiha FS; Torti FM
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1245-60. PubMed ID: 1723408
[TBL] [Abstract][Full Text] [Related]
33. Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Mann K; Clemm C; Wilmanns W
Anticancer Res; 1997; 17(4B):3047-9. PubMed ID: 9329598
[TBL] [Abstract][Full Text] [Related]
34. [Serum CA19-9 levels in testicular germ cell tumor patients].
Suzuki K; Tokue A
Hinyokika Kiyo; 2001 Jul; 47(7):467-72. PubMed ID: 11523129
[TBL] [Abstract][Full Text] [Related]
35. [Management of stage I testicular nonseminomatous germ cell tumors with an embryonic carcinomatous component. 18 cases].
Drianno N; Robert M; Legouffe E; Guiter J; Navratil H
Prog Urol; 1997 Sep; 7(4):622-7. PubMed ID: 9410322
[TBL] [Abstract][Full Text] [Related]
36. Immunochemical determination of human chorionic gonadotropin and alpha-fetoprotein in sera and tumors of patients with testicular cancer.
Javadpour N; McIntire KR; Waldmann TA
Natl Cancer Inst Monogr; 1978 Dec; (49):209-13. PubMed ID: 86162
[TBL] [Abstract][Full Text] [Related]
37. Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
Suurmeijer AJ; Oosterhuis JW; Marrink J; De Bruin HW; Schraffordt Koops H; Sleijfer DT; Fleuren GJ
Oncodev Biol Med; 1983; 4(4):289-308. PubMed ID: 6188132
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of pregnancy-specific beta 1-glycoprotein in patients with non-seminomatous testicular germ cell tumors.
de Bruijn HW; Suurmeijer AJ; Sleijfer DT; Koops HS; Ockhuizen T; Willemse PH; Marrink J
Eur J Cancer Clin Oncol; 1982 Oct; 18(10):911-6. PubMed ID: 6186495
[TBL] [Abstract][Full Text] [Related]
39. Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases.
Moran CA; Suster S; Koss MN
Cancer; 1997 Aug; 80(4):699-707. PubMed ID: 9264353
[TBL] [Abstract][Full Text] [Related]
40. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Takizawa A; Miura T; Fujinami K; Osada Y
Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
